4.13MMarket Cap-104P/E (TTM)
1.9799High1.8700Low14.01KVolume1.9000Open1.9400Pre Close26.72KTurnover0.67%Turnover RatioLossP/E (Static)2.10MShares31.000052wk High0.47P/B4.11MFloat Cap1.770052wk Low--Dividend TTM2.09MShs Float778.0000Historical High--Div YieldTTM5.67%Amplitude1.7700Historical Low1.9060Avg Price1Lot Size
Genprex Stock Forum
NEWS
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer
Genprex announced the first patient dosing in its Phase 1 Acclaim-3 clinical study of Reqorsa Immunogene Therapy in combination with Tecentriq to treat extensive-stage small cell lung cancer (ES-SCLC). This trial, which aims to determine the maximum tolerated dose for a Phase 2 expansion expected in the second half of 2024, ...
📊⚡️📊
No comment yet